pregabalin
Pregabalin (Lyrica) is an oral gabapentinoid used for neuropathic pain, adjunctive treatment of partial seizures, and generalised anxiety disorder in adults. It binds to calcium-channel subunits on overactive nerve cells, quieting the release of pain and excitatory signals. It is taken by mouth and is not a direct GABA agonist.
This page is based on the European Medicines Agency assessment report for Lyrica, cross-checked with MedlinePlus and the National Cancer Institute drug dictionary; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
Overactive nerves are like a fire alarm that won't stop ringing. Pregabalin turns down the volume on that alarm by sitting on the calcium 'doorbell' buttons at the end of nerve cells. With fewer calcium signals getting through, the nerves release less of the chemical messengers that carry pain, anxiety, and seizure signals, so the alarm quiets down without being switched off completely.
In simple terms
Pregabalin works by binding to specific subunits (called alpha-2-delta) on calcium channels at the ends of nerve cells in the brain and spinal cord. When nerves are overactive, calcium channels open too often and release large amounts of chemical messengers that carry pain, anxiety, and seizure signals. Pregabalin reduces the flow of calcium into these nerve endings, so fewer excitatory chemicals are released. This calms down overactive nerves without blocking normal nerve function. Pregabalin does not bind directly to GABA receptors, even though it is related in structure to the neurotransmitter GABA.
In depth
Pregabalin is a 3-isobutyl derivative of gamma-aminobutyric acid that selectively binds to the alpha-2-delta (A2D) auxiliary subunits of presynaptic voltage-dependent calcium channels (VDCCs) in the central nervous system. Binding prevents calcium influx and the subsequent calcium-dependent release of neurotransmitters, including glutamate, norepinephrine, serotonin, dopamine, and substance P, from hyperexcited nerve terminals. Synaptic transmission is inhibited and neuronal excitability is diminished. Pregabalin does not bind directly to GABA-A or GABA-B receptors and does not alter GABA uptake or degradation. The net effect is reduced excitatory neurotransmission in pain pathways, seizure foci, and anxiety circuits.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
How pregabalin turns down an overactive nerve alarm
- Overactive nerves are like a fire alarm that won't stop ringing.
- Pregabalin works by binding to specific subunits (called alpha-2-delta) on calcium channels at the ends of nerve cells in the brain and spinal cord.
- Pregabalin turns down the volume on that alarm by sitting on the calcium 'doorbell' buttons at the end of nerve cells.
- With fewer calcium signals getting through, the nerves release less of the chemical messengers that carry pain, anxiety, and seizure signals, so the alarm quiets down without being switched off completely.
Target: Alpha-2-delta subunit of voltage-dependent calcium channels
Pregabalin binds selectively to the alpha-2-delta (A2D) auxiliary subunits of presynaptic voltage-gated calcium channels in the central nervous system, reducing calcium influx and the subsequent release of excitatory neurotransmitters such as glutamate, norepinephrine, and substance P.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in European Union
EMA- Treatment of peripheral and central neuropathic pain in adults
- Adjunctive therapy in adults with partial seizures with or without secondary generalisation
- Treatment of generalised anxiety disorder (GAD) in adults
Approved uses in United States
MedlinePlus- Relief of neuropathic pain from diabetic peripheral neuropathy and postherpetic neuralgia
- Relief of neuropathic pain associated with spinal cord injury
- Treatment of fibromyalgia
- Adjunctive therapy for partial-onset seizures in adults and children 1 month of age and older
Official sources
The statements on this page trace back to these records.
- Lyrica (pregabalin) — Summary of product characteristics and package leaflet, English version
European Medicines Agency
- MedlinePlus: pregabalin
MedlinePlus, U.S. National Library of Medicine
- National Cancer Institute: pregabalin
National Cancer Institute
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.